Atara Biotherapeutics, Inc. — Director's Dealing 2019

Feb 8, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Atara Biotherapeutics, Inc. (ATRA)
CIK: 0001604464
Period of Report: 2019-02-06

Reporting Person: Kim Mina (Senior VP & General Counsel)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-02-06	Common Stock	A	17063	$0.00	Acquired	60063	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-02-06	Employee Stock Option (Right to Buy)	$38.47	A	34125	Acquired	2029-02-05	Common Stock (34125)	Direct

Footnotes

F1: These restricted stock units vest in four equal annual installments on each of the first, second, third and fourth anniversaries of the grant date, subject to the reporting person's continuous service.

F2: Includes 500 shares purchased on November 30, 2018 pursuant to the Issuer's Employee Stock Purchase Plan.

F3: 1/48th of the shares subject to the stock option vest and become exercisable each month following February 6, 2019, subject to the reporting person's continuous service..